Rizzo A - Search Results

1

Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes.

Rizzo A, Rinaldi L, Massafra R, Cusmai A, Guven DC, Forgia D, Latorre A, Giotta F. Rizzo A, et al. Future Oncol. 2024;20(20):1427-1434. doi: 10.1080/14796694.2024.2354162. Epub 2024 Jun 12. Future Oncol. 2024. PMID: 38864297

2

Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis.

Rizzo A, Mollica V, Ricci AD, Maggio I, Massucci M, Rojas Limpe FL, Fabio FD, Ardizzoni A. Rizzo A, et al. Future Oncol. 2020 Jan;16(2):4409-4418. doi: 10.2217/fon-2019-0429. Epub 2019 Dec 3. Future Oncol. 2020. PMID: 31793342

3

Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials.

Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Massari F. Rizzo A, et al. Future Oncol. 2022 Feb;18(5):625-634. doi: 10.2217/fon-2021-0888. Epub 2021 Dec 20. Future Oncol. 2022. PMID: 34927453 Review.

4

Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis.

Rizzo A, Mollica V, Santoni M, Ricci AD, Gadaleta-Caldarola G, Montironi R, Massari F. Rizzo A, et al. Future Oncol. 2022 Feb;18(6):739-748. doi: 10.2217/fon-2021-0841. Epub 2022 Jan 20. Future Oncol. 2022. PMID: 35048736 Review.

5

SARS-CoV-2 Omicron variant in cancer patients: an insight into the vaccine booster debate.

Rizzo A, Palmiotti G. Rizzo A, et al. Future Oncol. 2022 Apr;18(11):1301-1302. doi: 10.2217/fon-2022-0024. Epub 2022 Feb 3. Future Oncol. 2022. PMID: 35109688 Free PMC article. No abstract available.

6

Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential.

Rizzo A, Cusmai A, Acquafredda S, Rinaldi L, Palmiotti G. Rizzo A, et al. Expert Opin Investig Drugs. 2022 Jun;31(6):495-498. doi: 10.1080/13543784.2022.2042252. Epub 2022 Feb 17. Expert Opin Investig Drugs. 2022. PMID: 35171746 No abstract available.

7

Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand?

Rizzo A. Rizzo A. Future Oncol. 2022 May;18(14):1665-1668. doi: 10.2217/fon-2021-1623. Epub 2022 Feb 23. Future Oncol. 2022. PMID: 35193371 No abstract available.

8

Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.

Rizzo A, Ricci AD, Cusmai A, Acquafredda S, De Palma G, Brandi G, Palmiotti G. Rizzo A, et al. Curr Oncol. 2022 Jan 27;29(2):551-564. doi: 10.3390/curroncol29020050. Curr Oncol. 2022. PMID: 35200550 Free PMC article. Review.

9

Second-line fluoropyrimidine-based doublet chemotherapy for advanced biliary tract cancer: a new standard of care?

Rizzo A, Cusmai A, Palmiotti G. Rizzo A, et al. Expert Rev Gastroenterol Hepatol. 2022 Mar;16(3):201-203. doi: 10.1080/17474124.2022.2047652. Epub 2022 Mar 2. Expert Rev Gastroenterol Hepatol. 2022. PMID: 35220859 No abstract available.

10

Fluoropyrimidine-based doublet chemotherapy as second-line treatment for advanced biliary tract cancer: a meta-analysis of ABC-06 and NIFTY.

Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A, Palmiotti G. Rizzo A, et al. Expert Rev Gastroenterol Hepatol. 2022 Mar;16(3):273-278. doi: 10.1080/17474124.2022.2047651. Epub 2022 Mar 2. Expert Rev Gastroenterol Hepatol. 2022. PMID: 35220866

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,003 results

Search Page

Filters